Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$0.52 - $0.76 $6,402 - $9,357
12,312 New
12,312 $7,000
Q2 2022

Aug 15, 2022

BUY
$6.1 - $7.15 $61,036 - $71,542
10,006 Added 46.51%
31,519 $34,000
Q1 2022

May 16, 2022

BUY
$5.93 - $7.6 $20,114 - $25,779
3,392 Added 18.72%
21,513 $66,000
Q4 2021

Feb 14, 2022

BUY
$6.04 - $8.03 $28,877 - $38,391
4,781 Added 35.84%
18,121 $70,000
Q3 2021

Nov 15, 2021

BUY
$8.02 - $11.0 $106,986 - $146,740
13,340 New
13,340 $70,000
Q2 2021

Aug 11, 2021

SELL
$7.59 - $10.48 $103,983 - $143,576
-13,700 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$6.86 - $9.24 $93,982 - $126,588
13,700 New
13,700 $97,000

About Cyclacel Pharmaceuticals, Inc.


  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $4.01M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.